Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports. They presently have a $155.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 14.60% from the stock’s current price. Other research analysts have […]